usdaed

Last week, whispers of an ETF-a financial instrument as old as the hills-spun new life into this meme-born token. The promise of institutional embrace, however fleeting, spurred a frenzy of speculation. Yet now, as the REX-Osprey Dogecoin ETF draws near to its Sept. 17 debut, the token retreats, as if exhaling after a breathless sprint. Ah, the eternal rhythm of “buy the rumor, sell the news”-a romantic interlude where investors, like lovers, part ways with their gains, leaving the coin to linger in the twilight of its own success.

Last week, this here coin was prancing like a colt on a sugar rush, buoyed by whispers of rate cuts and the soft, warm glow of hope. But lo! The market’s been handed a double-edged razor-sharpened on one side by the promise of easier money, the other by the folly of 96.5 million fresh DOGEs flooding in, worth near $27 million. It’s a deluge, friend, and the levees of optimism ain’t built to hold it.

In the stillness before the market’s hum, an analyst from Leerink Partners, Mani Foroohar, gave his blessing to Scholar Rock, assigning it a rating of “outperform”-a subtle yet potent invitation to embrace the stock with eager arms. His target price: $51 per share, a number with a promise nearly 51% greater than Scholar Rock’s last closing price. For a company just beginning to cast its shadow, such growth seems almost inevitable. What is a stock’s rise but the shadow of a company’s soul reaching across the landscape, stirring the winds of fortune?

Arete Research, a smaller but respected equity research firm that has been covering technology, media, and telecommunications since 2000, has been tracking ASML since 2018. For the first time in seven years, Arete has upgraded the company’s stock from “hold” to “buy,” placing a price target of 879 euros. This comes as ASML currently trades near that target in U.S. dollars but is priced at 729.40 euros as of this writing. The research firm points to the anticipated surge in spending by Taiwan Semiconductor Manufacturing (TSMC), which, according to Arete’s estimations, will pour $50 billion into capital expenditures in both 2026 and 2027, up from a revised $38 to $42 billion this year.

Despite a not-insignificant downturn since July, IBM’s stock has maintained a relatively impressive upward trajectory. Over the past year, the shares have appreciated by approximately 20%, and over the past three years, the value has nearly doubled. A remarkable performance by any measure, this price appreciation underscores Wall Street’s growing obsession with IBM. Investors are drawn by the company’s increasing focus on quantum computing, cloud computing, and AI-a triumvirate that is seen as essential to the future of technology.